Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG0302-COVID19 vaccine in healthy adults
NCT04655625Phase 3Completed
- Sponsor
- AnGes, Inc.
- Start
- Nov 2020
- Primary completion
- Apr 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of AG0302 in coronavirus disease 2019 (COVID-19), sponsored by AnGes, Inc.. Started Nov 2020; status: completed.
02
Drugs
AG0302
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04655625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655625.